1. Home
  2. IOVA vs PRCH Comparison

IOVA vs PRCH Comparison

Compare IOVA & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • PRCH
  • Stock Information
  • Founded
  • IOVA 2007
  • PRCH 2012
  • Country
  • IOVA United States
  • PRCH United States
  • Employees
  • IOVA N/A
  • PRCH N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • PRCH Computer Software: Prepackaged Software
  • Sector
  • IOVA Health Care
  • PRCH Technology
  • Exchange
  • IOVA Nasdaq
  • PRCH Nasdaq
  • Market Cap
  • IOVA 975.1M
  • PRCH 1.1B
  • IPO Year
  • IOVA N/A
  • PRCH N/A
  • Fundamental
  • Price
  • IOVA $2.47
  • PRCH $9.80
  • Analyst Decision
  • IOVA Buy
  • PRCH Strong Buy
  • Analyst Count
  • IOVA 12
  • PRCH 10
  • Target Price
  • IOVA $10.36
  • PRCH $16.60
  • AVG Volume (30 Days)
  • IOVA 20.9M
  • PRCH 2.6M
  • Earning Date
  • IOVA 11-06-2025
  • PRCH 11-05-2025
  • Dividend Yield
  • IOVA N/A
  • PRCH N/A
  • EPS Growth
  • IOVA N/A
  • PRCH N/A
  • EPS
  • IOVA N/A
  • PRCH 0.27
  • Revenue
  • IOVA $250,425,000.00
  • PRCH $442,483,000.00
  • Revenue This Year
  • IOVA $65.15
  • PRCH N/A
  • Revenue Next Year
  • IOVA $58.47
  • PRCH $18.18
  • P/E Ratio
  • IOVA N/A
  • PRCH $36.23
  • Revenue Growth
  • IOVA 175.62
  • PRCH N/A
  • 52 Week Low
  • IOVA $1.64
  • PRCH $3.40
  • 52 Week High
  • IOVA $9.70
  • PRCH $19.44
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 57.23
  • PRCH 31.45
  • Support Level
  • IOVA $2.09
  • PRCH $8.81
  • Resistance Level
  • IOVA $2.55
  • PRCH $9.69
  • Average True Range (ATR)
  • IOVA 0.24
  • PRCH 0.70
  • MACD
  • IOVA 0.01
  • PRCH -0.02
  • Stochastic Oscillator
  • IOVA 61.59
  • PRCH 33.94

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.

Share on Social Networks: